Corticosteroid-induced glaucoma: a review of the literature
Corticosteroid-induced glaucoma: a review of the literature
复制标题
DOI：
10.1038/sj.eye.6701895
复制
发表时间：
2006-04-01
期刊：
影响因子：
3.9
通讯作者：
Broadway, DC
中科院分区：
文献类型：
--
作者：
Kersey, JP;Broadway, DC
眼压升高可使局部或全身皮质类固醇的使用复杂化，这一认识已有50年之久。最近，随着心肌蛋白基因（以前称为小梁网诱导糖皮质激素反应或TIGR基因）的分离，人们对这种类固醇反应现象重新产生了兴趣。此外，目前流行使用注射眼内类固醇治疗临床显著的视网膜下积液和黄斑水肿，导致发病率增加。动物研究、细胞生物学、分子生物学和遗传学知识的提高，使人们对这种反应背后的机制有了更好的了解。本综述的目的是描述发生皮质类固醇诱导的青光眼的危险因素，讨论该疾病的潜在机制和遗传学，并提出治疗方案。
The intraocular pressure rise that can complicate the use of topical or systemic corticosteroid has been recognised for 50 years. More recently, following isolation of the myocilin gene (previously known as the trabecular meshwork inducible glucocorticoid response or TIGR gene), there has been renewed interest in this steroid-responsive phenomenon. Furthermore, the currently fashionable use of injectable intraocular steroids in the management of clinically significant subretinal fluid and macular oedema has resulted in an increased incidence. Animal studies, cell biology, molecular biology, and an improved knowledge of genetics have provided a better understanding of the mechanisms behind the response. The purpose of this review is to describe the risk factors for developing corticosteroid-induced glaucoma, to discuss the underlying mechanisms and genetics of the condition and to present management options.